Lysophosphatidic Acid Signaling in Obesity and Insulin Resistance

被引:64
作者
D'Souza, Kenneth [1 ]
Paramel, Geena V. [1 ]
Kienesberger, Petra C. [1 ]
机构
[1] Dalhousie Univ, Fac Med, Dept Biochem & Mol Biol, Dalhousie Med New Brunswick, St John, NB E2L 4L5, Canada
基金
加拿大自然科学与工程研究理事会;
关键词
lysophosphatidic acid; lysophospholipids; autotaxin; obesity; insulin resistance; adipocytes; cardiovascular disease; diet; BROWN ADIPOSE-TISSUE; DIET-INDUCED OBESITY; PROTEIN-COUPLED RECEPTOR; NECROSIS-FACTOR-ALPHA; AUTOTAXIN EXPRESSION; GLUCOSE-HOMEOSTASIS; IN-VITRO; PREADIPOCYTE PROLIFERATION; ADIPOCYTE DIFFERENTIATION; CARDIOVASCULAR-DISEASE;
D O I
10.3390/nu10040399
中图分类号
R15 [营养卫生、食品卫生]; TS201 [基础科学];
学科分类号
100403 ;
摘要
Although simple in structure, lysophosphatidic acid (LPA) is a potent bioactive lipid that profoundly influences cellular signaling and function upon binding to G protein-coupled receptors (LPA1-6). The majority of circulating LPA is produced by the secreted enzyme autotaxin (ATX). Alterations in LPA signaling, in conjunction with changes in autotaxin (ATX) expression and activity, have been implicated in metabolic and inflammatory disorders including obesity, insulin resistance, and cardiovascular disease. This review summarizes our current understanding of the sources and metabolism of LPA with focus on the influence of diet on circulating LPA. Furthermore, we explore how the ATX-LPA pathway impacts obesity and obesity-associated disorders, including impaired glucose homeostasis, insulin resistance, and cardiovascular disease.
引用
收藏
页数:20
相关论文
共 134 条
[1]   Relationship between obesity, insulin resistance, and coronary heart disease risk [J].
Abbasi, F ;
Brown, BW ;
Lamendola, C ;
McLaughlin, T ;
Reaven, GM .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2002, 40 (05) :937-943
[2]   Shaping up the membrane: diacylglycerol coordinates spatial orientation of signaling [J].
Almena, Maria ;
Merida, Isabel .
TRENDS IN BIOCHEMICAL SCIENCES, 2011, 36 (11) :593-603
[3]   Serum lysophosphatidic acid is produced through diverse phospholipase pathways [J].
Aoki, J ;
Taira, A ;
Takanezawa, Y ;
Kishi, Y ;
Hama, K ;
Kishimoto, T ;
Mizuno, K ;
Saku, K ;
Taguchi, R ;
Arai, H .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, 277 (50) :48737-48744
[4]   Plasma lysophosphatidic acid concentration and ovarian cancer [J].
Baker, DL ;
Morrison, P ;
Miller, B ;
Riely, CA ;
Tolley, B ;
Westermann, AM ;
Bonfrer, JMG ;
Bais, E ;
Moolenaar, WH ;
Tigyi, G .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2002, 287 (23) :3081-3082
[5]   PHOSPHOINOSITIDES: TINY LIPIDS WITH GIANT IMPACT ON CELL REGULATION [J].
Balla, Tamas .
PHYSIOLOGICAL REVIEWS, 2013, 93 (03) :1019-1137
[6]   Elevated serum levels of lysophosphatidic acid in patients with multiple sclerosis [J].
Balood, Mohammad ;
Zahednasab, Hamid ;
Siroos, Bahaaddin ;
Mesbah-Namin, Seyed Alireza ;
Torbati, Sara ;
Harirchian, Mohammad Hossein .
HUMAN IMMUNOLOGY, 2014, 75 (05) :411-413
[7]   Molecular cloning and characterization of a novel human G-protein-coupled receptor, EDG7, for lysophosphatidic acid [J].
Bandoh, K ;
Aoki, J ;
Hosono, H ;
Kobayashi, S ;
Kobayashi, T ;
Murakami-Murofushi, K ;
Tsujimoto, M ;
Arai, H ;
Inoue, K .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (39) :27776-27785
[8]   Lysophosphatidic acid (LPA) receptors of the EDG family are differentially activated by LPA species - Structure-activity relationship of cloned LPA receptors [J].
Bandoh, K ;
Aoki, J ;
Taira, A ;
Tsujimoto, M ;
Arai, H ;
Inoue, K .
FEBS LETTERS, 2000, 478 (1-2) :159-165
[9]   Dominant negative mutations in human PPARγ associated with severe insulin resistance, diabetes mellitus and hypertension [J].
Barroso, I ;
Gurnell, M ;
Crowley, VEF ;
Agostini, M ;
Schwabe, JW ;
Soos, MA ;
Maslen, GL ;
Williams, TDM ;
Lewis, H ;
Schafer, AJ ;
Chatterjee, VKK ;
O'Rahilly, S .
NATURE, 1999, 402 (6764) :880-883
[10]   The adipocyte-secreted protein Acrp30 enhances hepatic insulin action [J].
Berg, AH ;
Combs, TP ;
Du, XL ;
Brownlee, M ;
Scherer, PE .
NATURE MEDICINE, 2001, 7 (08) :947-953